Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Cost of Revenue: 2011-2024

Historic Cost of Revenue for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $206.9 million.

  • Adma Biologics' Cost of Revenue fell 2.63% to $58.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $221.3 million, marking a year-over-year increase of 13.18%. This contributed to the annual value of $206.9 million for FY2024, which is 22.23% up from last year.
  • Latest data reveals that Adma Biologics reported Cost of Revenue of $206.9 million as of FY2024, which was up 22.23% from $169.3 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Cost of Revenue ranged from a high of $206.9 million in FY2024 and a low of $61.3 million during FY2020.
  • Moreover, its 3-year median value for Cost of Revenue was $169.3 million (2023), whereas its average is $165.0 million.
  • Data for Adma Biologics' Cost of Revenue shows a peak YoY skyrocketed of 48.95% (in 2022) over the last 5 years.
  • Adma Biologics' Cost of Revenue (Yearly) stood at $61.3 million in 2020, then surged by 30.15% to $79.8 million in 2021, then soared by 48.95% to $118.8 million in 2022, then soared by 42.47% to $169.3 million in 2023, then climbed by 22.23% to $206.9 million in 2024.